An international comparative policy analysis of opioid use disorder treatment in primary care across nine high-income jurisdictions
Kellia Chiu,Saloni Pandya,Manu Sharma,Ashleigh Hooimeyer,Alexandra de Souza,Abhimanyu Sud
DOI: https://doi.org/10.1016/j.healthpol.2024.104993
IF: 3.255
2024-01-14
Health Policy
Abstract:Background Opioid use disorder (OUD) and opioid-related harms are current health priorities in many high-income countries such as Canada. Opioid agonist therapy (OAT) is an effective evidence-based treatment for OUD, but access is often limited. Aims To describe and compare OUD treatment policies across nine international jurisdictions, and to understand how they are situated within their primary care and health systems. Methods Using policy documents, we collected data on health systems, drug use epidemiology, drug policies, and OUD treatment from Australia, Canada, France, Germany, Ireland, Portugal, Sweden, Switzerland, and Taiwan. We used the health system dynamics framework and adapted definitions of low- and high-threshold treatment to describe and compare OUD treatment policies, and to understand how they may be shaped by their health systems context. Results Broad similarities across jurisdictions included the OAT pharmacological agents used and the need for supervised dosing; however, preferred OAT, treatment settings, primary care and specialist physicians' roles, and funding varied. Most jurisdictions had elements of lower-threshold treatment access, such as the availability of treatment through primary care and multiple OAT options, but the higher-threshold criteria of supervised dosing. Conclusions From the Canadian perspective, there are opportunities to improve accessibility of OUD care by drawing on how different jurisdictions incorporate multidisciplinary care, regulate OAT medications, remunerate healthcare professionals, and provide funding for services.
health care sciences & services,health policy & services